source
- ADC Therapeutics shares plunge as Phase 3 trial of Zynlonta shows high death rate despite efficacy gainADC Therapeutics reported Phase 3 data for Zynlonta combined with rituximab in a hard-to-treat blood cancer. The trial met its primary endpoint by extending progression-free survival versus standar…
- Novo Nordisk Indiana plant faces FDA re-inspection after hair found in drugs and roof leaks threaten sterilityNovo Nordisk's fill‑finish facility in Bloomington, Indiana underwent a follow‑up FDA inspection in April. The agency reported mammalian hair in finished drug containers and identified water leaks…